← feed

Is NCT02298153 results overdue?

Yes — results are overdue. Primary completion was 2017-11-08; the FDAAA-801 reporting deadline (2018-11-08) passed 2782 days ago and no results are posted on ClinicalTrials.gov.

A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

NCT IDNCT02298153 ↗
SponsorIncyte Corporation (INDUSTRY)
Public issuerINCYTE CORP — INCY (CIK 0000879169) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusTERMINATED
Primary completion2017-11-08 (ACTUAL)
Reporting deadline2018-11-08 (completion + 365d)
Days overdue2782
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 ff8f758f58ee23bd… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02298153. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →